Prescient Therapeutics Limited has released a press release.
PTX-100 CTCL Phase 2a study reaches review milestone
Earlier from Prescient Therapeutics
- Prescient Therapeutics Opens SPP to Raise $7m Today
- Appendix 4E and 2026 Annual Report
- June 2026 Quarterly Update and Appendix 4C
- March 2026 Quarterly Update and Appendix 4C